Valuation : Glaukos Corporation

Market Cap 10.58B 9.11B 8.55B 7.82B 14.59B 1,001B 14.71B 101B 39.37B 511B 39.75B 38.88B 1,647B P/E 2026 *
-222x
P/E 2027 * 611x
Enterprise Value 10.41B 8.96B 8.4B 7.69B 14.35B 984B 14.47B 99.43B 38.72B 503B 39.09B 38.24B 1,620B EV / Sales 2026 *
15.1x
EV / Sales 2027 * 12.2x
Free-Float
96.35%
Yield 2026 *
-
Yield 2027 * -
1 day+0.46%
1 week-0.12%
Current month+0.44%
1 month+8.18%
3 months+62.80%
6 months+48.90%
Current year+59.73%
1 week 174.28
Extreme 174.28
182.28
1 month 167.64
Extreme 167.64
191.62
Current year 93.96
Extreme 93.96
191.62
1 year 73.16
Extreme 73.16
191.62
3 years 59.22
Extreme 59.22
191.62
5 years 33.33
Extreme 33.33
191.62
10 years 23.08
Extreme 23.075
191.62
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap. Importance
28/08/26 Sell

Executive/Senior Manager

-13,744 0.0240%
19/08/26 Exercice

Director

7,500 0.0131%
11/08/26 Exercice

Chairperson

180,000 0.3139%
Change 5-day change 1-year change 3-year change Capi.($)
+0.46%-0.12%+91.96%+140.82% 10.58B
-1.35%-6.58%-21.02%+8.28% 120B
-0.99%-1.77%-23.60%-1.17% 12.07B
-1.67%-2.76%-52.33%-70.90% 4.16B
+0.91%-10.65%-24.45%+36.04% 2.46B
-0.31%-2.57% - - 1.98B
-1.47%+0.55%-34.25%-73.98% 1.82B
-0.08%-6.19%-20.03%-25.18% 1.56B
-1.30%-6.98%-36.79%-42.54% 1.49B
Average -0.55%-3.01%-15.06%-3.58% 17.32B
Weighted average by Cap. -0.70%-4.48%-14.65%+13.15%

Financials

2026 *2027 *
Net sales 691M 594M 558M 510M 953M 65.31B 960M 6.6B 2.57B 33.37B 2.59B 2.54B 107B 845M 727M 682M 624M 1.16B 79.84B 1.17B 8.07B 3.14B 40.8B 3.17B 3.1B 131B
Net income -51.88M -44.64M -41.89M -38.33M -71.53M -4.9B -72.1M -496M -193M -2.51B -195M -191M -8.07B 18.93M 16.28M 15.28M 13.98M 26.09M 1.79B 26.3M 181M 70.4M 914M 71.07M 69.52M 2.94B
Net Debt -175M -150M -141M -129M -241M -16.53B -243M -1.67B -651M -8.45B -657M -642M -27.21B -273M -235M -220M -202M -376M -25.79B -379M -2.61B -1.01B -13.18B -1.02B -1B -42.45B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
03/09/26 US$180.35 +0.46% 610,183
02/09/26 US$179.53 +1.60% 768,719
01/09/26 US$176.70 -1.59% 507,237
31/08/26 US$179.56 -0.17% 455,572
28/08/26 US$179.87 -1.12% 553,529
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
180.35USD
Average target price
197.15USD
Spread / Average Target
+9.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock